Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW conjugate vaccine in infants and toddlers
NCT05794230Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (8 cohorts), sponsored by Sanofi. Primary endpoint: Serum bactericidal assay using human complement seroprotection. Started Mar 2023; status: completed.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT05794230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794230.